Similar articles for PMID: 30986908

Year	Number of Results
2001	1
2002	1
2007	4
2008	2
2009	1
2011	1
2012	4
2013	2
2014	5
2015	8
2016	19
2017	15
2018	6
2019	2
2020	2
2021	2
2024	0

1

New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2.

Hamdy R, Elseginy SA, Ziedan NI, Jones AT, Westwell AD. Hamdy R, et al. Molecules. 2019 Apr 2;24(7):1274. doi: 10.3390/molecules24071274. Molecules. 2019. PMID: 30986908 Free PMC article.

2

Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2.

Hamdy R, Elseginy SA, Ziedan NI, El-Sadek M, Lashin E, Jones AT, Westwell AD. Hamdy R, et al. Int J Mol Sci. 2020 Nov 26;21(23):8980. doi: 10.3390/ijms21238980. Int J Mol Sci. 2020. PMID: 33256166 Free PMC article.

3

New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents.

Hamdy R, Jones AT, El-Sadek M, Hamoda AM, Shakartalla SB, Al Shareef ZM, Soliman SSM, Westwell AD. Hamdy R, et al. Int J Mol Sci. 2021 Nov 12;22(22):12272. doi: 10.3390/ijms222212272. Int J Mol Sci. 2021. PMID: 34830153 Free PMC article.

4

Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents.

Hamdy R, Ziedan NI, Ali S, Bordoni C, El-Sadek M, Lashin E, Brancale A, Jones AT, Westwell AD. Hamdy R, et al. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1037-1040. doi: 10.1016/j.bmcl.2016.12.061. Epub 2016 Dec 27. Bioorg Med Chem Lett. 2017. PMID: 28087272 Free article.

5

Virtual screening, SAR, and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole as a novel Bcl-2 inhibitor.

Ziedan NI, Hamdy R, Cavaliere A, Kourti M, Prencipe F, Brancale A, Jones AT, Westwell AD. Ziedan NI, et al. Chem Biol Drug Des. 2017 Jul;90(1):147-155. doi: 10.1111/cbdd.12936. Epub 2017 Feb 24. Chem Biol Drug Des. 2017. PMID: 28067996 Free article.

6

Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents.

Hamdy R, Ziedan N, Ali S, El-Sadek M, Lashin E, Brancale A, Jones AT, Westwell AD. Hamdy R, et al. Bioorg Med Chem Lett. 2013 Apr 15;23(8):2391-4. doi: 10.1016/j.bmcl.2013.02.029. Epub 2013 Feb 14. Bioorg Med Chem Lett. 2013. PMID: 23474389

7

Therapeutics targeting Bcl-2 in hematological malignancies.

Ruefli-Brasse A, Reed JC. Ruefli-Brasse A, et al. Biochem J. 2017 Oct 23;474(21):3643-3657. doi: 10.1042/BCJ20170080. Biochem J. 2017. PMID: 29061914 Review.

8

A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.

Lavik AR, Zhong F, Chang MJ, Greenberg E, Choudhary Y, Smith MR, McColl KS, Pink J, Reu FJ, Matsuyama S, Distelhorst CW. Lavik AR, et al. Oncotarget. 2015 Sep 29;6(29):27388-402. doi: 10.18632/oncotarget.4489. Oncotarget. 2015. PMID: 26317541 Free PMC article.

9

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. Merino D, et al. Cancer Cell. 2018 Dec 10;34(6):879-891. doi: 10.1016/j.ccell.2018.11.004. Cancer Cell. 2018. PMID: 30537511 Free article. Review.

10

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.

Roberts AW, Huang D. Roberts AW, et al. Clin Pharmacol Ther. 2017 Jan;101(1):89-98. doi: 10.1002/cpt.553. Epub 2016 Nov 26. Clin Pharmacol Ther. 2017. PMID: 27806433 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

67 results

Results by year